O'Shaughnessy Ventures Funds Bioengineer's Injectable Blood Vessel Therapy
Event summary
- O'Shaughnessy Ventures awarded a $100,000 fellowship to Liam Aranda-Michel on July 7, 2026.
- Aranda-Michel is developing an injectable therapy for restoring blood circulation without surgery.
- Current treatments rely on drugs or invasive procedures with limited success.
- Aranda-Michel's approach delivers pre-formed vascular units directly into damaged tissue.
- He is an undergraduate at MIT and has co-developed open-source platforms for vascular research.
The big picture
O'Shaughnessy Ventures' backing of Aranda-Michel aligns with the broader trend of venture capital funding cutting-edge medical research. The injectable therapy, if successful, could disrupt the $X billion market for treatments addressing circulatory issues, offering a less invasive alternative to existing solutions.
What we're watching
- Clinical Validation
- How quickly Aranda-Michel can transition from lab research to human trials will determine the therapy's viability.
- Market Adoption
- Whether the injectable therapy can gain traction among patients and healthcare providers as a non-surgical option.
- Competitive Landscape
- The pace at which other bioengineering firms develop similar technologies could impact OSV's strategic positioning.
Related topics